Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
gene therapy
4
×
life sciences
4
×
biotech
boston top stories
national blog main
national top stories
new york blog main
san diego blog main
san francisco blog main
bluebird bio
boston
clinical trials
deals
hemophilia
new york top stories
san diego top stories
san francisco top stories
spinal muscular atrophy
vertex pharmaceuticals
zolgensma
adeno-associated virus
alexandria venture investments
alnylam pharmaceuticals
altitude life science ventures
ambys medicines
american society of gene and cell therapy
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
arch venture partners
astellas pharma
athenex
atlas venture
audentes therapeutics
avidity biosciences
bioinnovation capital
biolabs
biomarin pharmaceutical
boulder/denver blog main
What
long
4
×
drug
gene
help
therapy
ago
aren’t
bio
biotech
biotechs
considering
crude
cutting
data
despite
developers
diseases
driving
drugs
dyne
early
edge
effects
encoded
expected
experimental
eyes
fda
genetic
good
having
healthcare
history
humans
illumina’s
imminent
improved
industry
innovation
innovations
Language
unset
Current search:
long
×
photo
×
" life sciences "
×
" gene therapy "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
